Articles published by Cabaletta Bio
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
November 18, 2024
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
November 14, 2024
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
November 06, 2024
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
September 25, 2024
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
May 15, 2024
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 21, 2024
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
March 20, 2024
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
February 27, 2024
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
February 01, 2024
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
January 08, 2024
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
November 06, 2023
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
October 02, 2023
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
September 19, 2023
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201
August 22, 2023
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
From Cabaletta Bio
Via GlobeNewswire
Tickers
CABA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.